ArticlePloS one2013
Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Inflammation down-regulates CYP3A4-catalysed drug metabolism in hemodialysis patients.BMC pharmacology & toxicology · 2018Trial
- Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus.Nature communications · 2024Article
- Increased protein phosphatase 5 expression in inflammation-induced left ventricular dysfunction in rats.BMC cardiovascular disorders · 2022Article
- Inflammation-induced left ventricular fibrosis is partially mediated by tumor necrosis factor-α.Physiological reports · 2021Article
- Pentraxin-3-mediated complement activation in a swine model of renal ischemia/reperfusion injury.Aging · 2021Article
- Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Article
- Tissue Dependent Role of PTX3 During Ischemia-Reperfusion Injury.Frontiers in immunology · 2019Review
- Investigation of the Mechanism Underlying Calcium Dobesilate-Mediated Improvement of Endothelial Dysfunction and Inflammation Caused by High Glucose.Mediators of inflammation · 2019Article
- Pentraxin 3 in Cardiovascular Disease.Frontiers in immunology · 2019Review
- Membrane innovation: closer to native kidneys.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2018Review
- Hemodialysis Induces an Acute Decline in Cerebral Blood Flow in Elderly Patients.Journal of the American Society of Nephrology : JASN · 2018Article
- PTX3 in serum induces renal mesangial cell proliferation but has no effect on apoptosis.Experimental and therapeutic medicine · 2018Article
- Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update.Toxins · 2018Review
- Altered Protein Composition of Subcutaneous Adipose Tissue in Chronic Kidney Disease.Kidney international reports · 2017Article
- Relationship between plasma pentraxin 3 level and risk of chronic kidney disease in the Korean elderly: the Dong-gu study.International urology and nephrology · 2017Article
- Association of genetic variants of pentraxin 3 rs3816527 with hypertension in Chronic kidney disease patients.Molecular and cellular biochemistry · 2017Article
- The inflammatory protein Pentraxin 3 in cardiovascular disease.Immunity & ageing : I & A · 2016Review
- Novel association between serum pentraxin-2 levels and advanced fibrosis in well-characterised patients with non-alcoholic fatty liver disease.Alimentary pharmacology & therapeutics · 2015Article
- Correlation between arterial stiffness and inflammatory markers in autosomal dominant polycystic kidney disease patients with preserved renal function.International urology and nephrology · 2015Article
- Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.Clinical kidney journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Elevated systemic pentraxin 3 (PTX3) levels appear to be a powerful marker of inflammatory status and a superior outcome predictor in patients with chronic kidney disease (CKD). As previous data imply that PTX3 is involved in vascular pathology and that adipose tissue mass may influence circulating PTX3 levels, we aimed to study the importance of adipose tissue expression of PTX3 in the uremic milieu and its relation to endothelial dysfunction parameters. Plasma PTX3 and abdominal subcutaneous adipose tissue (SAT) PTX3 mRNA levels were quantified in 56 stage 5 CKD patients (median age 57 [range 25-75] years, 30 males) and 40 age and gender matched controls (median age 58 [range 20-79] years, 27 males). Associations between PTX3 measures and an extensive panel of clinical parameters, including surrogate markers of endothelial function, were assessed. Functional ex vivo studies on endothelial status and immunohistochemical staining for PTX3 were conducted in resistance subcutaneous arteries isolated from SAT. SAT PTX3 mRNA expression correlated with plasma PTX3 concentrations (rho = 0.54, p = 0.0001) and was increased (3.7 [0.4-70.3] vs. 1.2 [0.2-49.3] RQ, p = 0.02) in CKD patients with cardiovascular disease (CVD), but was not significantly different between patients and controls. The association to CVD was lost after adjustments. SAT PTX3 mRNA levels were independently correlated to asymmetric dimethylarginine and basal resistance artery tone developed after inhibition with nitric oxide synthase and cyclooxygenase (rho = -0.58, p = 0.002). Apparent positive PTX3 immunoreactivity was observed in both patient and control arteries. In conclusion, fat PTX3 mRNA levels are associated with measures of endothelial cell function in patients with CKD. PTX3 may be involved in adipose tissue-orchestrated mechanisms that are restricted to the uremic milieu and modify inflammation and vascular complications in CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.